NASDAQ:REVB Revelation Biosciences Q2 2026 Earnings Report $0.92 +0.01 (+1.05%) Closing price 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.09%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Revelation Biosciences EPS ResultsActual EPS-$0.87Consensus EPS -$0.88Beat/MissBeat by +$0.01One Year Ago EPSN/ARevelation Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARevelation Biosciences Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsRevelation Biosciences' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Revelation Biosciences Earnings HeadlinesRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyAugust 19, 2026 | finance.yahoo.comREVB approaching a critical inflection pointAugust 7, 2026 | msn.comJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2 trillion, with Anthropic and OpenAI preparing IPOs of their own. But Najarian's top pick isn't an IPO. It's a small American company with a $6 billion market cap powering Elon Musk's newest venture, dubbed the Infinite Power Grid. The full story is laid out in his newly released presentation.September 16 at 1:00 AM | Banyan Hill Publishing (Ad)Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights PlanJuly 10, 2026 | finanznachrichten.deREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comSee More Revelation Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email. Email Address About Revelation BiosciencesRevelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.View Revelation Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull CaseMarex Stock Doubles on Record Profits, But Can the Rally Continue?The Ultimate Cyber Shield: CrowdStrike Rises Past $2352 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
